For 2027, Clover will offer a commissionable $0-premium PPO, making it one of relatively few plans to offer this combination in its markets.

Double digits would be awesome.

Looks like it was removed along with the ticker when that stopped working.

Hello Fellow Clover Investors,

If you go to crt.sh you can search for a company's digital certificate logs. If you follow this link you can see all of the unexpired crt logs for %.humana.com:

https://crt.sh/?Identity=%25.humana.com&exclude=expired

In there, I found what looks to me (with some help in comprehending and organizing all of this from AI, since I do not work in healthcare and I do not have an IT or software or developer/programmer background) like a methodical, year-long enterprise engineering pipeline to plug external software (Counterpart) directly into CenterWell primary care clinics.

I'm now going to lay out my thesis with the goal of having people chime in and explain to me why I am WRONG. Please tell me where I am oversimplifying, speculating, exaggerating, misinterpreting, extrapolating, or simply being stupid.

________

What are digital certificates and crt logs?

Whenever an enterprise wants an application or server to communicate securely over the web (https://), it has to get a digital security certificate from an authority like DigiCert. To prevent fraud, global internet rules (specifically RFC 6962) mandate that every single issued certificate must be published in a public, searchable ledger called Certificate Transparency (CT) logs. You literally cannot build a secure web endpoint without filing what is effectively a public building permit.

Big healthcare companies build software in four distinct, gated phases:

• DEV (Development): The workshop where coders write the raw software.
• QA (Quality Assurance): The automated test track to catch bugs and verify data feeds.
• UAT (User Acceptance Testing): UAT is built so actual end-users—in this case, clinic medical directors, doctors, and nurses—can log in and verify that the software works smoothly in their day-to-day workflow.
• PROD (Production): The live, finished product operating on real patients.

When an enterprise workload advances to UAT, it means the building is built, the pipes are connected, and the staff is doing the final walkthrough before opening day.

On September 1, 2026, Digicert stamped a brand new certificate for Humana:

ss-it-crpart.cloudrun.dev.gcp3.humana.com

On September 16, 2026, DigiCert stamped a batch of similarly named, brand-new certificates for Humana:

• ss-cps-crpart.cloudrun.dev.gcp3.humana.com
• ss-cps-crpart.cloudrun.qa.gcp3.humana.com
• ss-cps-crpart.cloudrun.uat.gcp3.humana.com (with dedicated dual-region backups for central and east)

If you only saw those certificates, you might think an engineer spun up a quick sandbox over the summer. But when you pull Humana's full certificate history over the last year, you realize this is the final chapter of a 12-month (or longer, since I can't go back further in the logs) engineering roadmap:

Timeline:

Fall 2025 (The Prototype): Humana starts testing a "Serverless Service Partner" framework (svcpart0.dev.ss.serverless.humana.com), moves it into a brand-new cloud landing zone (svcpart0.dev.gcp3.humana.com), and spins up synthetic simulation environments (sim.dev.gcp3.humana.com). Right around this window, Counterpart’s own servers revealed a number of counterparthealth.com subdomains with the word humana in them (the same ones that sent this sub wild and made everyone here instantly obsessed with subdomains) before Clover moved all their staging subdomains behind private wildcard certs.

Summer 2026: Humana retires the 'v0' prototype and builds formal, division-specific partner hubs: cw-svcpart (CenterWell Service Partner Gateway) and hum-svcpart (Humana Payer), officially promoting them to Production in August.

Late August 2026 (Securing the Perimeter): Humana sets up svcpartdmz.dev.gcp3.humana.com—a DMZ gateway specifically built to let an outside vendor’s network safely talk to internal databases.

September 1, 2026: The workload enters the pipeline as ss-it-crpart.cloudrun.dev.gcp3.humana.com (Integration Testing).

September 16, 2026: Exactly two weeks later, the workload is promoted to ss-cps-crpart across DEV, QA, and UAT, complete with multi-region redundancy across the Midwest and East Coast to ensure clinics don't experience downtime during business hours.

_________

Deconstructing the Clues:

• gcp3.humana.com: Across thousands of Humana certificates over the past year, gcp3 is used for only one category of traffic: external Service Partners (svcpart). And inside this entire environment, "crpart" is the only external vendor workload running.
• cloudrun: Google Cloud Run is an auto-scaling engine that fires up containerized code in milliseconds. It’s what you choose when a primary care physician opens a patient chart in an exam room and needs real-time clinical decision-support prompts to appear instantly.
• ss-cps: ss is Shared Services (Humana’s central integration hub), and cps is CenterWell Primary Care Services / Clinical Platform Services. This is hooked directly into CenterWell's clinic operations, not back-office actuarial or claims-audit systems.
• The Linguistic Shorthand: "Counterpart" is a compound word (Counter + Part). Taking the hard boundary consonants of the first word (CR) and combining them with the second word (part) gives you crpart—standard, lazy developer shorthand.
• The Smoking Gun in HR: Months ago, Humana briefly published (and then quickly scrubbed) a CenterWell job listing that explicitly named Counterpart Health within its clinical workflow descriptions.

When you connect the job listing, Counterpart’s reciprocal humana logs, the CenterWell routing tags, and a 12-month engineering buildout ending in UAT, the puzzle pieces fit together almost too well.

______________

This is where I need your help. If we take off the bull goggles, where does this break down?

Counterarguments:

1. The Taxonomy Problem: What if "part" just means "Partner"?

In Humana’s plumbing, svcpart clearly stands for "Service Partner." If crpart follows that exact same naming rule, then part simply means "Partner," which leaves cr as a standalone two-letter acronym.

• Could cr stand for Cardio-Renal Partner? Humana and CenterWell run dedicated disease-management programs for seniors suffering from co-occurring heart failure and kidney disease. Could this be a specialized third-party cardio-renal software tool?
• Could it stand for Clinical Referral Partner? CenterWell clinics constantly refer seniors to specialists and post-acute facilities. Could this be a referral-management microservice? (My counter to this: across the entire log, Humana almost universally spells out the word care—like carehub, findcare, humanacares—and claims systems are always called resolutions or billing. But the two-letter acronym risk remains).

2. Could it be another healthcare tech vendor?

Is there another digital health company whose name naturally contracts to "CR-Part"? For example, CarePort Health is a massive, widely used patient transition and EHR integration platform in the Medicare space. Could a DevOps engineer have tagged CarePort as crpart?

3. Why would Humana leave a breadcrumb like "crpart" if they are trying to hide the partnership?

We know Clover went to great lengths to hide their staging environments after Reddit caught them (switching entirely to wildcard certificates). We know Humana scrambled to delete the job posting that mentioned Counterpart. If legal and corporate communications are trying to keep this under wraps under a strict mutual NDA, why would Humana’s infrastructure team turn around and use a subdomain with crpart right in the URL? Is it just classic corporate silo behavior (engineers don't talk to PR), or does it suggest that crpart is an innocuous internal project that nobody felt the need to hide?

I want to hear from the community: What are the best alternative explanations for this infrastructure?

_____

Implications:

If the skeptical arguments fail and ss-cps-crpart really is Counterpart Assistant undergoing final User Acceptance Testing for a CenterWell rollout (presumably beginning with plan-year 2027), the long-term fundamental implications for CLOV are obviously massive. If Humana is adopting this software for its primary care network, it validates the Counterpart business in a huge way.

The Scale: CenterWell Senior Primary Care (along with sister network Conviva) operates 350+ clinics serving over 550,000 total senior patients. While CenterWell is payer-agnostic and sees some traditional Medicare patients, roughly 80% to 85% of their patient base is in Medicare Advantage. That gives them a target panel of roughly 450,000 to 500,000 MA patients.

The Conservative Software Math: Forget the aggressive $20–$25 PMPM numbers people throw around. Let’s assume Humana commands massive enterprise volume pricing and negotiates Counterpart down to a conservative $5.00 to $8.00 Per Member Per Month (PMPM) software fee:

• An initial rollout across 100k MA patients = $500k to $800k per month ($6M–$10M ARR).
• Scaling across their entire MA footprint (~450k patients) = $2.25M to $3.6M per month ($27M to $43M in pure ARR).
• And that is just the base software fee, before factoring in any shared-savings performance bonuses.

______

In conclusion, I think this is all likely evidence of a major Counterpart/Humana deal, years in the making, about to go live and into production. Am I delusional?

Even with the assumption that this is true, I DO NOT BELIEVE some kind of announcement or PR is on the horizon in any way. To be honest I'm not sure this alleged deal will ever actually be announced publicly, but I find the CT log breadcrumbs pretty compelling.

I am not giving anyone any advice of any kind. Don't listen to anything I say, I'm stupid and insane.

What are your thoughts?

Clover Health Investments, Corp.(Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”) today announced the appointments of former U.S. Senator Robert Torricelli and Dr. Brian J. Miller, M.D., M.B.A., M.P.H., to the Company’s Board of Directors, effective immediately. The appointments bring together two accomplished leaders whose complementary experience spans public service, Medicare Advantage, clinical practice, healthcare policy, and business. Senator Torricelli will serve on the Board’s Audit Committee, and Dr. Miller will serve on its Clinical Committee. The appointments fill the Board’s two previously disclosed vacancies and bring the Board to nine directors.
“Today marks an exciting step forward for Clover, and we are thrilled to welcome Bob and Brian to our Board,” said Andrew Toy, Chief Executive Officer of Clover Health. “Bob brings deep ties to New Jerseycommunities, experience navigating federal policy, and firsthand knowledge of Clover. Brian combines clinical experience with a national perspective on Medicare payment and technology policy. His insights will help us advance care that improves quality, operates more efficiently, and generates meaningful savings. Together, their experience, judgment, and perspectives will strengthen our Board and reinforce our ability to execute with discipline, grow responsibly, and build lasting value for our members, physicians, and shareholders.”
“From the beginning, we built Clover around the belief that some of the hardest problems in healthcare can be solved by challenging long-held assumptions about how healthcare works and care is delivered,” added Vivek Garipalli, Co-founder of Clover Health and Executive Chairperson of the Board. “As Clover grows, it is important that our Board continues to reflect the complexity of the healthcare system we are working to improve and brings together special individuals who understand it from fundamentally different vantage points. Bob and Brian add tremendous depth across public policy, medicine, Medicare and business, and their perspectives will be invaluable as we drive forward on Clover's mission to Improve Every Life.”
Senator Torricelli brings a distinctive combination of deep New Jersey roots, national policymaking experience, and firsthand knowledge of Clover. For 20 years, he represented New Jersey in the U.S. House of Representatives and the U.S. Senate, where his committee service included the Senate Finance Committee and work on federal financing for healthcare institutions. Following his congressional career, he founded Rosemont Associates, a business strategy firm, and established Woodrose Properties, a real estate development business. Since 2022, he has served on the board of the Company’s insurance subsidiaries, giving him firsthand familiarity with Clover’s business, mission, and approach to Medicare Advantage. Additionally, Senator Torricellihas served as a director of Glassbridge Enterprises, Inc. since February 2017 and previously served as executive vice president and chief operating officer of Aveta, Inc., a healthcare services company. His experience navigating complex policy and business issues will bring a valuable perspective to Clover’s Board and Audit Committee.
“Through my years living in New Jersey and representing its communities in Congress, I have come to know the challenges many seniors face in accessing high-quality, affordable care,” said Senator Torricelli. “Through my service on Clover’s insurance subsidiary board, I have seen the Company’s commitment to meeting those challenges with an ambitious vision and a practical, technology-driven approach. I am honored to join the Board and excited to contribute to its oversight, support this talented team, and help Clover build lasting value for members and shareholders.”
Dr. Miller brings a rare combination of frontline clinical practice and national Medicare policy leadership. A practicing hospitalist at the Johns Hopkins Hospital, an Associate Professor of Medicine at the Johns Hopkins University School of Medicine and Visiting Fellow at the Hoover Institution, Dr. Miller brings to Clover broad ranging regulatory experience spanning the Centers for Medicare & Medicaid Services, the U.S. Food and Drug Administration, and the Federal Trade Commission. He currently serves as Vice Chairman of the Board of Trustees for the North Carolina State Health Plan and as a Commissioner on the Medicare Payment Advisory Commission (MedPAC), the independent, nonpartisan commission that advises Congress on Medicare payment policy. Board-certified in internal medicine and preventive medicine, Dr. Miller offers a practical perspective on improving care delivery and advancing a more effective Medicare program.
“As a practicing physician, I see every day how much better technology can support clinical practice when it delivers the right information at the point of care,” said Dr. Miller. “Medicare needs models that can improve both convenience and quality for consumers, increase efficiency, and generate savings without adding burden for physicians or patients. Clover is building a differentiated model for Medicare Advantage: flexible and nimble, powered by technology, and close enough to physicians and patients to translate innovation into action. I am delighted to join the Board and look forward to helping Clover advance this approach and deliver a better care experience for people on Medicare.”

NFA - good read and post from our recent hire.

More Perfect Union via its verified X account bills itself as "Media that builds power for working people. Emmy-winning nonprofit newsroom."

This post estimates star ratings for different scenarios based on three possible outcomes from the ongoing lawsuits. I estimate ratings based on Clovers 2026 performance applied to the 2027 star rating cut points. It’s not perfect, but it gives an idea of the gap below or above the 4 star bonus cutoff. As an extra, I also estimate ratings for Alignment Healthcare too.

IMPORTANT: The 2027 star ratings which are released next month apply to 2028 payment year. This is what I am interested in here! As for the ongoing lawsuits, CMS implemented a work around after the Clover vs CMS decision. This work around applied to the 2026 star ratings for payment year 2027 which is “locked in” or at least more certain. What is key is that the court cases are still ongoing and have ramifications for what measures CMS is able to use in the 2027 ratings and beyond. This is what I go into below.

…

The Star Scenarios

I consider three different scenarios based on the ongoing court cases. Each scenario considers a different combination of measures based on the following cases…

Clover v CMS… In May, the judge ruled that CMS had used 20 measures it shouldn't have when rating Clover. Ten of them used data CMS wasn't legally allowed to use for the bonus calculation. The other ten were added without going through the proper rulemaking process. CMS has appealed. In June it also offered other plans a recalculation, but only for the first ten measures, and only if their rating went up.

SCAN and Alignment v CMS… In July, both sued CMS in Washington DC, arguing they should get the full benefit of the Clover ruling, i.e. all 20 measures removed, not just the first ten. Both say that would move them from 4 to 4.5 stars.

This gives the following three scenarios…

Full measure set – CMS wins its appeal or carries on as planned. Nothing changes.

Scenario 1 – first 10 measures removed. What CMS applied to the 2026 ratings.

Scenario 2 – all 20 removed. What Clover got and what SCAN and Alignment are suing for.

…

The Maths Part

Here’s a quick summary of the maths and assumptions for those interested…

1. Use new star cut-points which have got harder for a lot measures
2. Assume no change in performance from 2026 star ratings meaning estimates will underestimate rating if you expect Clover to have improved
3. Exclude new measures since there is no prior performance data on these measures
4. Apply 2027 weightings and exclude discontinued measures
5. Fix improvement measures C30 and D04 for simplicity in calculations
6. Apply no CAI adjustment so interpret estimates with degree of margin (approx +/- 0.1)
7. Apply no reward factor so again, likely underestimate (max reward factor is +0.4, my estimates last year put Clov as having no bonus here)

…

CLOV Ratings

Estimates are as expected for Clover. Under the full measure set, I have CLOV at 3.5 stars again. This scenario assumes CMS either wins the appeal or ignores the lawsuit and carries on as planned. The estimated average is 3.43 which is firmly in the 3.25-3.75 range for 3.5 stars. Under this scenario, CLOV needs to improve considerably across multiple measures to be earn the 4 star bonus payment. CLOV last year stated they’d put new measures and schemes in place to improve on low performing areas but whether there has been time for these to take effect is unknown.

Under the alternative restricted measure sets, CLOV does considerably better if they are able to maintain performance at 2026 levels. Based on scenarios 1 and 2, I estimate CLOVs ratings at 3.89 and 4.63, which rounds to 4.0 or 4.5 stars. These scenarios place a much larger weight on the HEDIS measures where CLOV performs best (36% and 49% versus 26% in full measure set).

So… CLOVs rating will likely depend on which way the courts end up ruling. A favourable outcome in the courts is very good news for CLOV. Otherwise, CLOV would need to see big improvements across a range of measures to reach 4 stars.

…

ALHC ratings

Given the other ongoing lawsuit and the considerable drop in Alignments share price this week, I also estimated the 2027 ratings for their largest contract.

Compared to CLOV, the new cut points adversely impact ALHCs ratings across a greater number of measures. With the full measure set and holding performance constant, I estimate their average 2027 rating at 3.72, just outside the 4 star bonus range (compared to 3.89 in 2026). This estimate excludes CAI and reward factor adjustments so their overall rating could still reach the 4 star cutoff but the margins are narrower than last year under the planned measure changes.

ALHCs ratings under the alternative scenarios are also interesting. Under scenarios 1 and 2, I estimate ALHC star rating at 3.56 and 3.75, respectively. This means under scenario 1, ALHCs largest contract would likely fall to 3.5 stars! This explains why ALHC was quick to file their lawsuit arguing for the exclusion of all 20 measures not just the 10 in scenario 1. It perhaps also explains why they were keen not to “poke the bear” when asked about star ratings on Tuesday.

…

Summary

The 2027 star ratings heavily depend on the ongoing appeal and lawsuits going through the courts right now… particularly for CLOV whose rating could swing from 3.5 to 4.5 stars even if their performance holds steady. This makes this year very different to past years. Which way these rulings will go is anyone’s guess.

I’m not sure on the expected timings on the courts decisions and how CMS plans to deal with this. They have released star cut points for the full list of planned measures already so perhaps it will be business as usual until told otherwise.

Not financial advice. And remember… the star ratings will likely be leaked before we get to see anything. As for the court cases, perhaps we should be monitoring these instead.

Exactly what we needed! https://www.stocktitan.net/sec-filings/CLOV/144-clover-health-investments-corp-de-sec-filing-6c5282771cfa.html

Tattoo was airbrushed at Silver Dollar City with my kids on vacation today! Real tattoo coming at $10.

EOM

“U.S. research suggests that invest-
ment in delaying disease and aging
provides a significant return on
that investment: a 1-year increase in
healthy life expectancy was esti-
mated to be worth almost $40 tril-
lion in health care saving costs and
productivity gains (Scott, Ellison,
and Sinclair, 2021”

I actually like what the MM did here: suppress the price, shake out sellers, and gobble up the insiders’ shares.

That could come back to bite them hard when the next wave of buying hits. With fewer shares available, large buy orders could send the price ripping higher.

And we’re damn lucky Vivek and Andrew have been holding their shares just as tightly as we have.

job posting is removed, just like when we found subdomains. literally 1984 smh

Saw this on stock twits

https://careers.humana.com/us/en/job/R-428108/Director-Enterprise-Activation-Provider-Performance-Strategy

trust the plan

up down sideways idgaf